Harvey Pitt, Kalorama Partners CEO & former SEC chairman, weighs in on the feud between Carl Icahn and Bill Ackman over Herbalife. "It's starting to look like Ackman is trying to get the stock price lower than it is currently trading at," Pitt says.» Read More
"Of course we like the deal," says Carl Icahn, of Icahn Enterprises, who owns a 6% stake in El Paso. "It's a win-win for both of them."
Mad Money's Cramer says investors can always fall back on high-yielding dividend stocks that pay you to wait, like Clorox. Discussing the future of the company, now that it turned down Carl Icahn's $80/share bid, with Donald Knauss, Clorox CEO.
Collin Gillis, BGC Partners technology analyst weighs in on RIMM's pop in trading this morning.
Debating whether Carl Icahn's bid for Clorox was a realistic deal, with the Fast Money traders.
CNBC's David Faber provides insight on why Carl Icahn withdrew his proxy fight at Clorox.
CNBC's Brad Goode has the story on the settlement agreement between Icahn and Lionsgate.
Billionaire investor Carl Icahn has decided to go after the Clorox board, reports CNBC's David Faber. And a look at the beating HP is taking today.
Volatility last week has left some scars, says Jim Iuorio, TJM Institutional Services. "People seem to be ready to tip toe back into the stock market," he says.
Clorox shares dropped again today as investors question whether Carl Icahn will manage to seal a deal with the company, with the Fast Money team.
Digging deep into the SEC filings to see what the billionaires are doing with their holdings. CNBC's Brian Sullivan has the details.
Billionaire investor Carl Ichan ups Forest Labs stake to 20 million from 5 million, with the Fast Money crew.
Forest Laboratories said it won backing from proxy advisory firm ISS for all 10 of its board nominees in a proxy battle with billionaire investor Carl Icahn.
Carl Icahn, activist investor, explains why the market selloff is "completely overdone," and why he is buying right now.
CNBC's David Faber reports Clorox's board unanimously rejected Carl Icahn's latest offer, saying it substantially undervalues the company.
Motorola Mobility landed on the trader radar Thursday after Carl Icahn urged the company to explore alternatives for its patent portfolio.
CNBC's David Faber has the story on whether the billionaire investor is bluffing when he says there's no question he'll be able to raise $7.8 billion to buy the company.
Clorox likely to draw limited interest from strategic buyers, say a number of analysts, with the Fast Money team.
Analysis of billionaire Carl Ichan's bid for the company and whether the stock has room to run, Bill Schmitz, Deutsche Bank Securities, and Javier Escalante, Weeden & Company.
Clorox is "very undervalued," and given the current economic environment "it would be no problem for us to buy it," billionaire investor Carl Icahn told CNBC Friday.
Discussing the internet company's blowout quarter and bright future, with Ken Sena, Evercore Partners, and the Fast Money traders weigh in on Google, Clorox, and natural gas trades to make today.